Prediction of Coronary Artery Disease Using Urinary Proteomics

Study design and participants

The study was a retrospective longitudinal study, comprised of a discovery cohort and a validation cohort (Figure 1). The discovery cohort consisted of 36 cases and 36 matched controls from a population-based study, the Flemish Study on Environment, Genes, and Health Outcomes (FLEMENGHO).⁷ Cases were individuals asymptomatic for CAD at baseline but progressed to CAD during a median of 8.3-year (interquartile [IQR]: 5.5-9.8) follow-up. CAD was defined as myocardial infarction, acute coronary syndrome, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, any fatal ischemic heart disease. Cases and controls with an averaged estimated glomerular filtration rate of 80.5 (IQR: 71.0-89.3) ml/min/1.73m² were matched for sex, age, history of hypertension, antihypertensive treatment, and total cholesterol. The validation cohort was comprised of 893 individuals (115 with and 778 without CAD) from the FLEMENGHO study (35 with and 702 without CAD) or extracted from the Human Urinary Proteome Database (80 with and 76 without CAD), consisting of more than 85000 samples from various clinical and research centers.¹⁴ All the latter datasets were fully anonymized and previously published, with respective references provided below. Demographic and clinical characteristics from extracted datasets included sex, age, hypertension, diabetes, office blood pressure, and estimated glomerular filtration rate (eGFR). The second use of FLEMENGHO study data (B32220083510) was approved by the University of Leuven Ethics Committee and participants provided written informed consent. Datasets extracted from the Human Urinary Proteome Database were previously published and relevant studies were conducted in compliance with the Helsinki declaration for research in humans and received an approval from the responsible review boards.^{13, 15-17} CAD endpoint was defined as myocardial infarction, acute coronary syndrome, new-onset angina pectoris, ischemic cardiomyopathy, and coronary revascularization.

• Download figure
• Open in new tab

Figure 1. The schematic diagram of study design.

In the biomarker discovery phase, urinary proteome analysis was performed on 36 patients who progressed to CAD and 36 matched controls. A total of 160 urinary peptides were identified to be significantly different between cases and controls and their biological function was elucidated by bioinformatic analysis. Simultaneously, 160 peptides were used to construct a classifier for the discrimination of CAD by the supervised machine learning method, and the predictive performance and prognostic value were evaluated by an independent validation cohort. CAD, coronary artery disease.

Urinary proteome analysis

Urinary proteome analysis was performed with a P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Fullerton, CA) coupled to a micrOTOF MS (Bruker Daltonics, Bremen, Germany). MosaFinder software was used to process mass spectral data and to generate a raw list of peptides or small proteins before being annotated according to prior sequenced peptides from the Human Urinary Proteome Database.¹⁴ Peptide intensities were normalized using 29 collagen peptides, serving as an internal standards, being in general not affected by the disease, to assure comparability between different datasets.¹⁸ Further information on sample preparation, data processing, and sequencing of the peptides was described elsewhere.^{9, 19, 20}

Classifier construction

Distinct peptides between individuals who progressed to reach an CAD endpoint and controls were identified in the discovery cohort. Urinary sequenced peptides identified in ≥ 30% of either cases or controls were analyzed. Peptide abundances was compared using the non-parametric Wilcoxon test, followed by adjustment for multiple testing. Peptides were considered statistically significant when the P-value was less than 0.05 after adjustment for multiple testing by Benjamini-Hochberg correction. The statistical validity of significant peptides was further confirmed by permutation analysis that randomly excluded 30% of the samples with 10 times repetition. Peptides with a nominal P-value of <0.05 in more than 50% of the permutation analyses were considered for further analysis. The support vector machine (SVM), a supervised machine learning algorithm, was applied to construct a classifier for the discrimination of CAD using the significant peptides. Model construction and parameters tuning were performed with the MosaCluster software.²¹ The model ‘s generalization was examined by take-one-out cross-validation.

Statistical analysis

Statistical analysis was conducted with SAS software, version 9.4 (SAS Institute, Cary, NC, USA). Means and percentages were compared using a t-test or analysis of variance (ANOVA) test, or Fisher ‘s test as appropriate. Statistical significance was considered as a two-sided P value of 0.05. Time-dependent receiver operating characteristic (ROC) curves and the areas under the ROC curves (AUC) were used to estimate the predictive capacity of the new classifier for incident CAD at 3, 5, and 8 years. The predictive capacity of previously developed classifiers, CAD238 and ACSP75 were assessed as comparisons.^10-13 The AUC estimate and 95% confidence interval (CI) for each classifier were calculated using the PHREG procedure to fit the Cox regression model in SAS. Moreover, whether the addition of the urinary proteomic classifier could improve risk reclassification for CAD on top of the Framingham risk score was further evaluated. The Framingham risk score was calculated based on common clinical risk factors, including sex, age, systolic blood pressure, smoking, diabetes, treatment of hypertension, total cholesterol, and high-density lipoprotein cholesterol.²² The improvement in risk reclassification was evaluated by net reclassification index (NRI) and integrated discrimination index (IDI). P value and 95% confidence interval (CI) of NRI and IDI were estimated by 500 times bootstrap. The prognostic value of the new classifier was assessed by multivariable Cox proportional hazard models. Model 1 was adjusted for covariates, including sex, age, mean arterial blood pressure, and diabetes. Model 2 was additionally adjusted for eGFR. Hazard ratio (HR) and 95% CI was estimated for per-SD increment in a classifier score or using the bottom quartile of a classifier score as a reference.

Bioinformatics analysis

To better interpret the underlying mechanisms between identified urinary peptides and CAD, the proteolysis processes that produced the polypeptides were considered. The potential proteases were predicted based on the N- and C-terminal cleavage sites of peptides by the Proteasix Knowledge Base (http://www.proteasix.org).²³ With the observed prediction mode, the cleavage sites were matched based on the literature. Subsequently, the parental proteins of the peptides, together with the predicted proteases were submitted for pathway enrichment analysis to elucidate their biological functions. The pathway analysis was performed via the ClueGO plug-in (v 2.5.7) of Cytoscape v 3.7.2 using the Reactome pathway database (updated on 8, May 2020).^{24, 25} The minimum number of proteins to enrich a pathway was 3 and the minimum enrichment ratio was 4%. The significant threshold of P-values corrected by the Bonferroni step-down was 0.05. The clusters were based on pathway connectivity assessed by the predefined kappa score threshold of 0.4. And the cluster name was represented by the most significant pathway in a cluster.

Participant characteristics

In the discovery cohort, the mean age was 58.4 (standard deviation [SD]: 12.2) years and 27.8% were female. The baseline characteristics between individuals with and without CAD endpoints were similar in the discovery set (P ≥ 0.078), except for eGFR (mean: 75.1 ± 17.0 vs. 83.1 ± 14.1, P = 0.038, Table 1). Of 893 participants in the validation cohort, the mean age was 52.7(16.3) years, and 446 (49.9%) were women. Individuals who progressed to CAD endpoints tended to be male, older, having a history of hypertension, diabetes, and lower eGFR, compared to those without CAD endpoints (P ≤ 0.014, Table 2).

Urinary proteomic classifiers and the prediction of CAD

In the discovery cohort, a total of 518 sequenced peptides significantly differed between individuals with and without CAD after multiple testing corrections and permutation tests.

Subsequently, a urinary proteomic classifier integrating 160 significant peptides was developed in the discovery cohort using the SVM (regularization parameter: 64, kernel coefficient: 0.000256, epsilon: 0.001). When generalizing the new classifier to the independent validation cohort, this new classifier provided an AUC of 0.77 (95%CI: 0.70-0.84), 0.83 (95%CI: 0.76-0.86), and 0.82 (95%CI: 0.78-0.87) for the prediction of CAD endpoints at 3, 5, and 8-year, consistently outperforming to prior classifiers, CAD238 and ACSP75 (Table 3). Moreover, the addition of the new classifier significantly improved AUC on top of CAD238 (from 0.65-0.71 to 0.79-0.85) and ACSP75 (from 0.53-0.61 to 0.77-0.84). The combination of three classifiers yielded an increased AUC of 0.79 (0.73-0.85), 0.85 (0.78-0.87), and 0.84 (0.80-0.89) for the prediction of 3, 5, and 8-year CAD. Furthermore, the risk reclassification was improved by the addition of the new classifier on top of the Framingham risk score in 737 individuals from the FLEMENGHO study, as suggested by an NRI of 0.61 (95% CI: 0.25-0.95, P = 0.001) and IDI of 0.02 (95% CI: 0.02-0.05, P = 0.39).

Association between urinary proteomic classifier with CAD

The association between the new classifier and the risk of CAD is presented in Table 4. In the multivariable-adjusted model, a 1-SD increment in the new classifier was associated with a 1.62-fold (95% CI: 1.34-1.96) higher risk of incident CAD at 8-year follow-up. Compared with individuals in the bottom quartile of the new classifier, those in the highest quartile had a significantly higher risk of CAD (HR: 3.55, 95% CI: 1.84-6.85) after adjustment. When additionally adjusting for eGFR, slightly weakened associations that remained significant (HR: 1.54, 95% CI: 1.26-1.89 for 1-SD increment) were observed for the new classifier. Neither CAD238 nor ACSP75 was significantly associated with CAD after adjustment. Moreover, for 737 individuals from the FLEMENGHO study, the new classifier was positively associated with CAD (adjusted HR: 1.44, 95% CI: 1.01-2.95 for 1-SD increment), independent of the Framingham risk score.

Urinary peptides associated with CAD

These 160 urinary peptides were fragments of 58 parental proteins, mainly derived from collagens, such as collagen type I alpha I chain (36 peptide, 22.5%), collagen type III alpha chain (22 peptide, 13.8%), and collagen type I alpha II chain (9 peptides, 5.6%). Of 160 urinary peptides, most peptides were higher in individuals with CAD, except for 27 peptides from collagen type I alpha I chain (7 peptides), collagen type III alpha chain (5 peptides), uromodulin (6 peptides), apolipoprotein C-II (1 peptide), sarcalumenin (1 peptide), collagen type 1 alpha I (1 peptide), collagen type III alpha 1 (2 peptides), and collagen V alpha 2 (1 peptide). Table S1 in the supplementary materials displays the list of 160 peptides, fold-change in individuals with CAD, and their parental proteins. The elevated excretion of most collagen I and III fragments in individuals with CAD might suggest an upregulated collagen degradation. In addition to collagens, other prominent proteins, including fibrinogen (10 peptides), uromodulin (7 peptides), polymeric immunoglobulin receptor (3 peptides), CD99 antigen (2 peptides), and insulin (2 peptides), and insulin-like growth factors II were upregulated in participants with CAD. The remaining parental proteins functioned diversely, including lipid metabolism (apolipoprotein C-II, apolipoprotein C-III, apolipoprotein L1, clusterin), proliferation (thymosin beta-4), tissue remodeling (clusterin), immune response (complement C4-A, complement factor B), inflammation (interleukin-1 receptor antagonist protein).

Bioinformatics was performed to obtain a comprehensive overview of the proteases that could lead to the generation of peptides associated with CAD. According to the cleavage sites, 11 proteases were predicted to participate in the fragmentation of proteins associated with CAD. Peptides that were higher in individuals with CAD predicted 11 up-regulated matrix metalloproteinases (MMPs) that mainly involve in collagen degradation, including MMP 1, 2, 8, 9, 13, 14, cathepsin K, and neuroendocrine convertase 1. Down-regulated peptides predicted lower activity of MMP 2 and 9 as well. (Table S2 in the supplementary materials).

The parental proteins of urinary peptides and their upstream proteases might be involved in the pathogenesis of CAD. Pathway enrichment analysis mapped 8 clusters consisting of 41 pathways (Figure 2 and Table S3 in the supplementary materials). The major pathways enriched were extracellular matrix turnover and signaling, cell surface interactions, plasma lipoprotein metabolism, activation of MMP, complement cascade, proliferation, and insulin processing.

• Download figure
• Open in new tab

Figure 2. Pathway enrichment analysis based on the parental proteins and predicted proteases of 160 urinary peptides.

Enriched pathways involved in seven clusters: extracellular matrix turnover and signaling (cluster 1), cell surface interactions at the vascular wall (cluster 2), plasma lipoprotein assembly, remodeling, and clearance (cluster 3), activation of matrix metalloproteinases (cluster 4), complement cascade (cluster 5), regulation of IGF transport and uptake by IGFBPs (cluster 6), insulin processing (cluster 7). All displayed pathways had P-value < 0.05. Enrichment ratio represents the number of submitted proteins in a particular pathway to the total number of proteins in the pathway. ECM, extracellular matrix; LPL, lipoprotein lipase; LIPC, hepatic lipase; MET, receptor tyrosine kinase; NCAM1, neural cell adhesion molecule. NGF, nerve growth factor; PDGF, platelet-derived growth factor; PTK, protein tyrosine kinase; IGF, insulin-like growth factor; IGFBP, Insulin-like growth factor binding protein.

Strengths and limitations

Our study has several strengths, including systematic urinary proteome analyses with good reproducibility, validation of the urinary proteomic in an independent, relatively large cohort, and assessment of the prognostic value. There are several limitations of our study. First, the association between the urinary proteomic classifier and the severity or subtypes of coronary events was not investigated, which requires a large, prospective study. Second, future studies are warranted to further evaluate whether the urinary proteomic classifier can identify plaque volume and composition measured by ultrasound or computerized tomography. Correlating urinary biomarkers with subclinical lesions could help to determine when interventions, such as statin therapy, should be initiated. Last, pathway analysis of these peptides relied on existing studies, thus their roles in the development of CAD might be different, which needs to be determined in preclinical experimental and epidemiological studies.